A Single-blind, Single Dose, Placebo Controlled, First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of GSK249320 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Refanezumab (Primary)
- Indications Neurodegenerative disorders
- Focus Adverse reactions; Biomarker
- Sponsors GlaxoSmithKline
- 12 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Mar 2008 New trial record.